Ownership and insider activity for NovaBridge Biosciences (NBP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors.
Price
| Price | $1.57 |
| Market Cap | $181M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $307.9M | $1.59B | $1.14B | $4.76B | $552.8M | $3.21B | $291.5M | $498.2M | $30.1M |
| Short-term Investments | $266.2M | $256.0M | $32.0M | $31.5M | $118.2M | $235.4M | $20.2M | $767.4M | $30021 |
| Receivables | $4.1M | $9.4M | $55.3M | $357.9M | $61.0M | $4.8M | $1.8M | 0 | $256327 |
| Inventory | 0 | 0 | -$55.9M | 0 | $4.3M | -$80.3M | 0 | 0 | 0 |
| Total Current Assets | $691.6M | $2.04B | $1.36B | $5.34B | $750.2M | $3.63B | $329.9M | $1.29B | $31.1M |
| Property, Plant & Equipment | $22.3M | $27.7M | $46.5M | $40.3M | $24.9M | $124.0M | $5.6M | $27.7M | $421589 |
| Goodwill | $162.6M | $162.6M | $162.6M | $162.6M | $25.5M | $162.6M | 0 | 0 | 0 |
| Intangible Assets | $148.8M | $148.8M | $148.8M | $120.4M | $18.8M | $118.9M | 0 | 0 | 0 |
| Total Assets | $1.03B | $2.38B | $1.74B | $6.33B | $878.7M | $4.07B | $368.9M | $1.55B | $37.2M |
| Accounts Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | $99.0M | $80.0M | $50.0M | 0 | 0 | $2.7M | 0 | 0 | 0 |
| Total Current Liabilities | $195.1M | $346.2M | $588.5M | $576.1M | $97.9M | $659.7M | $58.1M | $61.7M | $3.8M |
| Long-term Debt | $114.0M | $67.0M | $68.2M | $5.5M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $1.33B | $3.33B | $3.77B | $712.2M | $163.4M | $1.07B | $126.3M | $84.1M | $4.2M |
| Retained Earnings | -$357.9M | -$1.01B | -$2.49B | -$2.02B | -$683.2M | -$6.77B | -$1.26B | -$9.39B | -$190.5M |
| Total Equity | $410.5M | -$955.1M | $1.07B | $5.63B | $715.3M | $3.01B | $242.6M | $1.47B | $33.0M |
| Total Debt | $213.0M | $147.0M | $132.5M | $19.1M | $17.6M | $38.3M | $3.9M | $28.3M | $438458 |
| Net Debt | -$361.2M | -$1.70B | -$1.04B | -$4.77B | -$653.3M | -$3.41B | -$307.8M | -$1.24B | -$29.7M |
| Working Capital | $496.4M | $1.69B | $772.8M | $4.77B | $652.3M | $2.97B | $271.8M | $1.23B | $27.3M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 7.64 |
Profitability
| Return on Equity | -1.45% |
| Return on Invested Capital | -29.03% |
| Return on Assets | -21.17% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ALT · ANNX · AURA · DMAC · DRTS · DSGN · ENGN
Explore sector: Healthcare · Biotechnology
More sections of NBP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks